Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

Inclusion Criteria: * Total body weight between 50 and 115 kg * Hgb \> 12 gm/dl * Platelets \> 100,000/μL * ANC \> 1000/μL * Creatinine \< 1.5 mg/dl * SGPT and SGOT \< 3 X the institutional upper limit of normal (ULN) * Total bilirubin \< 1.5 X the institutional ULN (subjects with a higher level of bilirubin due to a familial metabolism will be considered on an individual basis) * Life expectancy greater than 2 years * Male subjects must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and until study completion (i.e., at least two weeks after dose of study drug) * Ability to understand and the willingness to sign a written informed consent document * Agree to refrain from use of selenium supplements while on study Exclusion Criteria: * Not willing to remain at RPCI, and in follow up, as required * Presence of medical conditions, which in the opinion of the investigators, would compromise either the subject, or the integrity of the data * Individuals with a history of active liver or kidney disease within the past 6 months * Treatment with an investigational drug within 30 days prior to the dose of study drug * Use of prescription or nonprescription drugs, vitamins, or herbal supplements known to change gastric acidity (e.g., H2-antagonists, proton pump inhibitors, antacids) within 3 days of study drug administration * History of allergic reactions attributed to compounds of similar chemical or biologic composition to MSC (e.g. reaction to other selenium supplements) * Subjects who have donated 1 unit of blood within 30 days prior to the first dose of MSC * Subjects with a known history of heavy metal exposure, such as lead, mercury, of arsenic * ECOG performance status \> 1 * AUA total symptom score \> 10 (or any individual symptom score of greater than or equal to 4 will exclude the participant)